1. +
Lichtman
MA: Historical landmarks in the understanding of the lymphomas, in Neoplastic Diseases of the Blood, ed 5, edited by Wiernik
PH, Goldman
JM, Dutcher
J, Kyle
RA, p 789. Springer, New York, 2013.
2. +
Swerdlow
SH, World Health Organization, International Agency for Research on Cancer, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization International Agency for Research on Cancer, Lyon, France 2008.
3. +
Fisher
SG, Fisher
RI: The epidemiology of non-Hodgkin’s lymphoma. Oncogene 23:38, 2004.
4. +
Morton
LM, Wang
SS, Devesa
SS
et al.: Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:1, 2006.
5. +
Alexander
DD, Mink
PJ, Adami
HO
et al.: The non-Hodgkin lymphomas: A review of the epidemiologic literature.
Int J Cancer 120:1, 2007.
[PubMed: 17405121]
6. +
Ye
BH, Lista
F, Lo Coco
F
et al.: Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262:5134, 1993.
7. +
Dalla-Favera
R, Migliazza
A, Chang
CC
et al.: Molecular pathogenesis of B cell malignancy: The role of BCL-6.
Curr Top Microbiol Immunol 246:257, 1999.
[PubMed: 10396064]
8. +
Gaidano
G, Lo Coco
F, Ye
BH
et al.: Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma: Association with diffuse large-cell subtype. Blood 84:2, 1994.
9. +
Lo Coco
F, Ye
BH, Lista
F
et al.: Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin’s lymphoma. Blood 83:7, 1994.
10. +
Ye
BH, Chaganti
S, Chang
CC
et al.: Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 14:24, 1995.
11. +
Kaneita
Y, Yoshida
S, Ishiguro
N
et al.: Detection of reciprocal fusion 5
′-BCL6/partner-3
′ transcripts in lymphomas exhibiting reciprocal BCL6 translocations.
Br J Haematol 113:3, 2001.
[PubMed: 11328273]
12. +
Chang
CC, Ye
BH, Chaganti
RS
et al.: BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A 93:14, 1996.
13. +
Lo Coco
F, Gaidano
G, Louie
DC
et al.: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:8, 1993.
14. +
Alizadeh
AA, Eisen
MB, Davis
RE
et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:6769, 2000.
15. +
Rosenwald
A, Wright
G, Chan
WC
et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:25, 2002.
16. +
Rosenwald
A, Wright
G, Leroy
K
et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:6, 2003.
17. +
Wright
G, Tan
B, Rosenwald
A
et al.: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100:17, 2003.
18. +
Lenz
G, Wright
GW, Emre
NC
et al.: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105:36, 2008.
19. +
Morin
RD, Johnson
NA, Severson
TM
et al.: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:2, 2010.
20. +
Morin
RD, Mendez-Lago
M, Mungall
AJ
et al.: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:7360, 2011.
21. +
Morin
RD, Mungall
K, Pleasance
E
et al.: Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Blood 122:7, 2013.
[PubMed: 23984448]
22. +
Davis
RE, Ngo
VN, Lenz
G
et al.: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:7277, 2010.
23. +
Ngo
VN, Young
RM, Schmitz
R
et al.: Oncogenically active MYD88 mutations in human lymphoma. Nature 470:7332, 2011.
24. +
Aviles
A, Neri
N, Huerta-Guzman
J: Large bowel lymphoma: An analysis of prognostic factors and therapy in 53 patients. J Surg Oncol 80:2, 2002.
25. +
Paryani
S, Hoppe
RT, Burke
JS
et al.: Extralymphatic involvement in diffuse non-Hodgkin’s lymphoma.
J Clin Oncol 1:11, 1983.
[PubMed: 6366124]
26. +
van Besien
K, Ha
CS, Murphy
S
et al.: Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:4, 1998.
27. +
Doggett
RS, Wood
GS, Horning
S
et al.: The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 115:2, 1984.
28. +
Stein
H, Lennert
K, Feller
AC, Mason
DY: Immunohistological analysis of human lymphoma: Correlation of histological and immunological categories.
Adv Cancer Res 42:67, 1984.
[PubMed: 6395656]
29. +
Yamaguchi
M, Seto
M, Okamoto
M
et al.:
De novo CD5+ diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients.
Blood 99:3, 2002.
[PubMed: 11756145]
30. +
Craig
FE, Foon
KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:8, 2008.
31. +
Stauder
R, Eisterer
W, Thaler
J, Gunthert
U: CD44 variant isoforms in non-Hodgkin’s lymphoma: A new independent prognostic factor. Blood 85:10, 1995.
32. +
Ottensmeier
CH, Stevenson
FK: Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood 96:7, 2000.
33. +
Cheson
B, Pfistner
B, Gascoyne
R: Revised response criteria for malignant lymphoma. J Clin Oncol 25:5, 2007.
34. +
Chen
MG, Prosnitz
LR, Gonzalez-Serva
A, Fischer
DB: Results of radiotherapy in control of stage I and II non-Hodgkin’s lymphoma. Cancer 43:4, 1979.
35. +
Jones
SE, Miller
TP, Connors
JM: Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 7:9, 1989.
36. +
Longo
DL, Glatstein
E, Duffey
PL
et al.: Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol 7:9, 1989.
37. +
Monfardini
S, Banfi
A, Bonadonna
G
et al.: Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 6:2, 1980.
38. +
Nissen
NI, Ersboll
J, Hansen
HS
et al.: A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin’s lymphomas.
Cancer 52:1, 1983.
[PubMed: 6406037]
39. +
Tondini
C, Zanini
M, Lombardi
F
et al.: Combined modality treatment with primary
CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s lymphomas.
J Clin Oncol 11:4, 1993.
40. +
Vokes
EE, Ultmann
JE, Golomb
HM
et al.: Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol 3:10, 1985.
41. +
Miller
TP, Dahlberg
S, Cassady
JR
et al.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma.
N Engl J Med 339:1, 1998.
[PubMed: 9647872]
42. +
Miller
TP, Leblanc
M, Spier
C
et al.:
CHOP alone compared to
CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphomas: Update of the Southwest Oncology Group (SWOG) randomized trial.
Blood 98:11, 2001.
43. +
Horning
SJ, Weller
E, Kim
K
et al.: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484.
J Clin Oncol 22:15, 2004.
[PubMed: 14657229]
44. +
Bonnet
C, Fillet
G, Mounier
N
et al.:
CHOP alone compared with
CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d’Etude des Lymphomes de l’Adulte.
J Clin Oncol 25:7, 2007.
45. +
Reyes
F, Lepage
E, Ganem
G
et al.: ACVBP versus
CHOP plus radiotherapy for localized aggressive lymphoma.
N Engl J Med 352:12, 2005.
46. +
Persky
DO, Unger
JM, Spier
CM
et al.: Phase II study of
rituximab plus three cycles of
CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
J Clin Oncol 26:14, 2008.
47. +
Phan
J, Mazloom
A, Medeiros
J
et al.: Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with
R-CHOP chemotherapy.
J Clin Oncol 28:27, 2010.
48. +
Held
G, Murawski
N, Ziepert
M
et al.: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 31:15, 2014.
49. +
DeVita
VT
Jr, Canellos
GP, Chabner
B
et al.: Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1:7901, 1975.
50. +
Gaynor
ER, Ultmann
JE, Golomb
HM, Sweet
DL: Treatment of diffuse histiocytic lymphoma (DHL) with COMLA (
cyclophosphamide, Oncovin,
methotrexate, leucovorin, cytosine arabinoside): A 10-year experience in a single institution.
J Clin Oncol 3:12, 1985.
[PubMed: 3855309]
51. +
Schein
PS, DeVita
VT
Jr, Hubbard
S
et al.:
Bleomycin, Adriamycin,
cyclophosphamide,
vincristine, and
prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Ann Intern Med 85:4, 1976.
52. +
Fisher
RI, DeVita
VT
Jr, Hubbard
SM
et al.: Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med 98:3, 1983.
53. +
Gordon
LI, Harrington
D, Andersen
J
et al.: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (
CHOP) for advanced diffuse non-Hodgkin’s lymphoma.
N Engl J Med 327:19, 1992.
[PubMed: 1598097]
54. +
Fisher
RI, Gaynor
ER, Dahlberg
S
et al.: Comparison of a standard regimen (
CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.
N Engl J Med 328:14, 1993.
55. +
Coiffier
B, Lepage
E, Briere
J
et al.:
CHOP chemotherapy plus
rituximab compared with
CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
N Engl J Med 346:4, 2002.
56. +
Feugier
P, Van Hoof
A, Sebban
C
et al.: Long-term results of the
R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte.
J Clin Oncol 23:18, 2005.
57. +
Habermann
TM, Weller
EA, Morrison
VA
et al.: Rituximab-CHOP versus
CHOP alone or with maintenance
rituximab in older patients with diffuse large B-cell lymphoma.
J Clin Oncol 24:19, 2006.
58. +
Pfreundschuh
M, Schubert
J, Ziepert
M
et al.: Six versus eight cycles of bi-weekly CHOP-14 with or without
rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60).
Lancet Oncol 9:2, 2008.
[PubMed: 18177811]
59. +
Pfreundschuh
M, Trumper
L, Osterborg
A
et al.: CHOP-like chemotherapy plus
rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group.
Lancet Oncol 7:5, 2006.
60. +
Cunningham
D, Hawkes
E, Jack
A
et al.:
Rituximab plus
cyclophosphamide,
doxorubicin,
vincristine, and
prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Lancet 381:9880, 2013.
61. +
Delarue
R, Tilly
H, Mounier
N
et al.: Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14:6, 2013.
62. +
Recher
C, Coiffier
B, Haioun
C
et al.: Intensified chemotherapy with ACVBP plus
rituximab versus standard
CHOP plus
rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial.
Lancet 378:9806, 2011.
63. +
Lai
GM, Chen
YN, Mickley
LA
et al.: P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49:5, 1991.
64. +
Gutierrez
M, Chabner
BA, Pearson
D
et al.: Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH: J Clin Oncol 18:21, 2000.
65. +
Wilson
WH, Bates
SE, Fojo
A
et al.: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
J Clin Oncol 13:8, 1995.
[PubMed: 7799047]
66. +
Wilson
WH, Grossbard
ML, Pittaluga
S
et al.: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 99:8, 2002.
67. +
Wilson
WH, Dunleavy
K, Pittaluga
S
et al.: Phase II study of dose-adjusted EPOCH and
rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
J Clin Oncol 26:16, 2008.
[PubMed: 18165634]
69. +
Haioun
C, Lepage
E, Gisselbrecht
C
et al.: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: Updated results of the prospective study LNH87–2. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 15:3, 1997.
70. +
Kluin-Nelemans
HC, Zagonel
V, Anastasopoulou
A
et al.: Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 93:1, 2001.
71. +
Santini
G, Salvagno
L, Leoni
P
et al.: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: Results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 16:8, 1998.
72. +
Verdonck
LF, van Putten
WL, Hagenbeek
A
et al.: Comparison of
CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma.
N Engl J Med 332:16, 1995.
73. +
Gisselbrecht
C, Lepage
E, Molina
T
et al.: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:10, 2002.
74. +
Haioun
C, Lepage
E, Gisselbrecht
C
et al.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87–2 protocol—A Groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18:16, 2000.
75. +
Kaiser
U, Uebelacker
I, Abel
U
et al.: Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol 20:22, 2002.
76. +
Stiff
P, Unger
J, Cook
J
et al.: Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med 369:18, 2013.
77. +
Greb
A, Bohlius
J, Schiefer
D
et al.: High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults.
Cochrane Database Syst Rev 1:CD004024, 2008.
[PubMed: 18254036]
78. +
Maurer
M, Ghesquieres
H, Jais
J: Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32:10, 2014.
80. +
Shipp
MA, Takvorian
RC, Canellos
GP: High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin’s lymphoma.
Am J Med 77:5, 1984.
[PubMed: 6741984]
81. +
Bajetta
E, Buzzoni
R, Valagussa
P, Bonadonna
G:
Mitoxantrone: An active agent in refractory non-Hodgkin’s lymphomas.
Am J Clin Oncol 11:2, 1988.
82. +
Wiernik
PH, Lossos
IS, Tuscano
JM
et al.:
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma.
J Clin Oncol 26:30, 2008.
83. +
Rizzieri
DA, Sand
GJ, McGaughey
D
et al.: Low-dose weekly
paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
Cancer 100:11, 2004.
84. +
Kewalramani
T, Zelenetz
AD, Nimer
SD
et al.:
Rituximab and
ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
Blood 103:10, 2004.
85. +
Velasquez
WS, McLaughlin
P, Tucker
S
et al.: ESHAP—An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 12:6, 1994.
86. +
Gisselbrecht
C, Glass
B, Mounier
N
et al.: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the
rituximab era.
J Clin Oncol 28:27, 2010.
87. +
Philip
T, Guglielmi
C, Hagenbeek
A
et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:23, 1995.
88. +
Chopra
R, Goldstone
AH, Pearce
R
et al.: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 10:11, 1992.
89. +
Rezvani
AR, Norasetthada
L, Gooley
T
et al.: Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: A multicentre experience.
Br J Haematol 143:3, 2008.
[PubMed: 18573107]
90. +
Thomson
KJ, Morris
EC, Bloor
A
et al.: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin’s lymphoma.
J Clin Oncol 27:3, 2009.
91. +
Krishnan
A, Nademanee
A, Fung
HC
et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 26:1, 2008.
92. +
Vose
JM, Bierman
PJ, Enke
C
et al.: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol 23:3, 2005.
93. +
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project.
N Engl J Med 329:14, 1993.
[PubMed: 8099429]
94. +
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89:11, 1997.
95. +
Zhou
Z, Sehn
L, Rademaker
A
et al.: An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the
rituximab era.
Blood 123:6, 2014.
96. +
Hans
CP, Weisenburger
DD, Greiner
TC
et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Blood 103:1, 2004.
97. +
Shipp
MA, Ross
KN, Tamayo
P
et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.
Nat Med 8:1, 2002.
[PubMed: 11786879]
98. +
Lossos
IS, Czerwinski
DK, Alizadeh
AA
et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:18, 2004.
99. +
Swan
F
Jr, Velasquez
WS, Tucker
S
et al.: A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:10, 1989.
100. +
Savage
K, Johnson
N, Ben-Neriah
S
et al.: MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with
R-CHOP chemotherapy.
Blood 114:17, 2009.
101. +
Kluk
M, Chapuy
B, Sinha
P
et al.: Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PloS One 7:4, 2012.
103. +
Buchmann
I, Reinhardt
M, Elsner
K
et al.: 2-(fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 91:5, 2001.
104. +
Spaepen
K, Stroobants
S, Dupont
P
et al.: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:2, 2001.
105. +
Zucca
E, Conconi
A, Mughal
TI
et al.: Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.
J Clin Oncol 21:1, 2003.
[PubMed: 12506161]
106. +
Gundrum
JD, Mathiason
MA, Derek
BM
et al.: Primary testicular diffuse large B-cell lymphoma: A population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of
rituximab.
J Clin Oncol 27:5227, 2009.
[PubMed: 19770371]
107. +
Pingali
S, Go
RS, Gundrum
JD
et al.: Adult testicular lymphoma in the United States (1985–2004): Analysis of 3,669 cases from the National Cancer Data Base (NCDB). J Clin Oncol 26(15S):19503, 2008.
108. +
Fonseca
R, Habermann
TM, Colgan
JP
et al.: Testicular lymphoma is associated with a high incidence of extranodal recurrence.
Cancer 88:1, 2000.
[PubMed: 10618598]
109. +
Visco
C, Medeiros
LJ, Mesina
OM
et al.: Non-Hodgkin’s lymphoma affecting the testis: Is it curable with doxorubicin-based therapy? Clin Lymphoma 2:1, 2001.
110. +
Pentheroudakis
G, Pavlidis
N: Cancer and pregnancy: Poena magna, not anymore. Eur J Cancer 42:2, 2006.
111. +
Pereg
D, Koren
G, Lishner
M: Cancer in pregnancy: Gaps, challenges and solutions. Cancer Treat Rev 34:4, 2008.
112. +
Pereg
D, Koren
G, Lishner
M: The treatment of Hodgkin’s and non-Hodgkin’s lymphoma in pregnancy. Haematologica 92:9, 2007.
113. +
Aviles
A, Diaz-Maqueo
JC, Torras
V
et al.: Non-Hodgkin’s lymphomas and pregnancy: Presentation of 16 cases. Gynecol Oncol 37:3, 1990.
114. +
Evens
AM, Advani
R, Press
OW
et al.: Lymphoma occurring during pregnancy: Antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 31:32, 2013.
115. +
Resnik
R: Cancer during pregnancy. N Engl J Med 341:2, 1999.
116. +
van Besien
K, Kelta
M, Bahaguna
P: Primary mediastinal B-cell lymphoma: A review of pathology and management. J Clin Oncol 19:6, 2001.
117. +
Savage
KJ, Monti
S, Kutok
JL
et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:12, 2003.
118. +
Perrone
T, Frizzera
G, Rosai
J: Mediastinal diffuse large-cell lymphoma with sclerosis. A clinicopathologic study of 60 cases. Am J Surg Pathol 10:3, 1986.
119. +
Zinzani
PL, Martelli
M, Bertini
M
et al.: Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: A retrospective multinational study on 426 previously untreated patients. Haematologica 87:12, 2002.
120. +
Todeschini
G, Secchi
S, Morra
E
et al.: Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicentre Italian experience in 138 patients treated with
CHOP or MACOP-B/VACOP-B:
Br J Cancer 90:2, 2004.
121. +
Dunleavy
K, Pittaluga
S, Maeda
L
et al.: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:15, 2013.
122. +
Katzenstein
AL, Carrington
CB, Liebow
AA: Lymphomatoid granulomatosis: A clinicopathologic study of 152 cases.
Cancer 43:1, 1979.
[PubMed: 83902]
123. +
Gitelson
E, Al-Saleem
T, Smith
MR: Review: Lymphomatoid granulomatosis: Challenges in diagnosis and treatment. Clin Adv Hematol Oncol 7:1, 2009.
124. +
Dunleavy
K, Janik
J, Cohen
J
et al.: 16. Clinical-pathological correlations: 079 Study of the treatment and biology of lymphomatoid granulomatosis (LYG); a rare EBV lymphoproliferative disorder. Ann Oncol 16:v59, 2005.
125. +
Ferreri
AJ, Campo
E, Seymour
JF
et al.: Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant.”
Br J Haematol 127:2, 2004.
[PubMed: 15384971]
126. +
Ferreri
AJ, Dognini
GP, Campo
E
et al.: Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 92:4, 2007.
127. +
Murase
T, Nakamura
S: An Asian variant of intravascular lymphomatosis: An updated review of malignant histiocytosis-like B-cell lymphoma. Leuk Lymphoma 33:5, 1999.
128. +
Murase
T, Nakamura
S, Kawauchi
K
et al.: An Asian variant of intravascular large B-cell lymphoma: Clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 111:3, 2000.
129. +
Shimazaki
C, Inaba
T, Nakagawa
M: B-cell lymphoma-associated hemophagocytic syndrome.
Leuk Lymphoma 38:1, 2000.
[PubMed: 10811443]
130. +
Ponzoni
M, Ferreri
AJ, Campo
E
et al.: Definition, diagnosis, and management of intravascular large B-cell lymphoma: Proposals and perspectives from an international consensus meeting. J Clin Oncol 25:21, 2007.
131. +
Ferreri
AJ, Dognini
GP, Govi
S
et al.: Can
rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?
J Clin Oncol 26:31, 2008.
132. +
Shimada
K, Matsue
K, Yamamoto
K
et al.: Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 26:19, 2008.
133. +
Oton
AB, Wang
H, Leleu
X
et al.: Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma 49:9, 2008.
134. +
Adami
J, Gabel
H, Lindelof
B
et al.: Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 89:7, 2003.
135. +
Tsao
L, Hsi
ED: The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Pathol Lab Med 131:8, 2007.
136. +
Cockfield
SM, Preiksaitis
JK, Jewell
LD, Parfrey
NA: Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
Transplantation 56:1, 1993.
[PubMed: 8333031]
137. +
Swinnen
LJ, Costanzo-Nordin
MR, Fisher
SG
et al.: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 323:25, 1990.
138. +
Walker
RC, Paya
CV, Marshall
WF
et al.: Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
J Heart Lung Transplant 14:2, 1995.
[PubMed: 7727471]
139. +
Hanto
DW: Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies.
Annu Rev Med 46:381, 1995.
[PubMed: 7598473]
140. +
Leblond
V, Davi
F, Charlotte
F
et al.: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity?
J Clin Oncol 16:6, 1998.
[PubMed: 9440716]
141. +
Kew
CE 2nd, Lopez-Ben
R, Smith
JK
et al.: Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation 69:5, 2000.
142. +
Rees
L, Thomas
A, Amlot
PL: Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppression. Lancet 352:9130, 1998.
143. +
Tsai
DE, Hardy
CL, Tomaszewski
JE
et al.: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients.
Transplantation 71:8, 2001.
[PubMed: 11211200]
144. +
Choquet
S, Leblond
V, Herbrecht
R
et al.: Efficacy and safety of
rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study.
Blood 107:8, 2006.
145. +
Trappe
R, Riess
H, Babel
N
et al.: Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent
rituximab.
Transplantation 83:7, 2007.
[PubMed: 17220782]
146. +
Swinnen
LJ, LeBlanc
M, Grogan
TM
et al.: Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 86:2, 2008.
147. +
Achten
R, Verhoef
G, Vanuytsel
L, De Wolf-Peeters
C: T-cell/histiocyte-rich large B-cell lymphoma: A distinct clinicopathologic entity. J Clin Oncol 20:5, 2002.
148. +
Abramson
JS: T-cell/histiocyte-rich B-cell lymphoma: Biology, diagnosis, and management.
Oncologist 11:4, 2006.
[PubMed: 16971734]
149. +
Aki
H, Tuzuner
N, Ongoren
S
et al.: T-cell-rich B-cell lymphoma: A clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leuk Res 28:3, 2004.
150. +
Bouabdallah
R, Mounier
N, Guettier
C
et al.: T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: A matched-control analysis. J Clin Oncol 21:7, 2003.
151. +
Boudova
L, Torlakovic
E, Delabie
J
et al.: Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 102:10, 2003.
152. +
Greer
JP, Macon
WR, Lamar
RE
et al.: T-cell-rich B-cell lymphomas: Diagnosis and response to therapy of 44 patients. J Clin Oncol 13:7, 1995.
153. +
McBride
JA, Rodriguez
J, Luthra
R
et al.: T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin’s disease. Am J Surg Pathol 20:2, 1996.
154. +
Rodriguez
J, Pugh
WC, Cabanillas
F: T-cell-rich B-cell lymphoma. Blood 82:5, 1993.
155. +
Willemze
R, Jaffe
ES, Burg
G
et al.: WHO-EORTC classification for cutaneous lymphomas. Blood 105:10, 2005.
156. +
Grange
F, Beylot-Barry
M, Courville
P
et al.: Primary cutaneous diffuse large B-cell lymphoma, leg type: Clinicopathologic features and prognostic analysis in 60 cases.
Arch Dermatol[Archives of Dermatology Full Text] 143:9, 2007.
158. +
Kodama
K, Massone
C, Chott
A
et al.: Primary cutaneous large B-cell lymphomas: Clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 106:7, 2005.
159. +
Beltran
B, Castillo
J, Salas
R
et al.: ALK-positive diffuse large B-cell lymphoma: Report of four cases and review of the literature.
J Hematol Oncol 2:11, 2009.
[PubMed: 19250532]
160. +
Reichard
KK, McKenna
RW, Kroft
SH: ALK-positive diffuse large B-cell lymphoma: Report of four cases and review of the literature. Mod Pathol 20:3, 2007.